Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is
pleased to announce that it has completed all the Company’s
required tasks in preparation for its planned upcoming regulatory
submission for Fexapotide Triflutate for the treatment of
BPH.
"Speaking for Management, we are extremely
pleased that all the external factors which had caused some
moderate delays this past year are behind us at this time." said
Paul Averback, CEO of Nymox. "We hope that our supporters
understand that there are many complex parts involved, and these
times have seen certain adjustments that we and many other groups
have had to handle with some patience. Given the usual seasonal
delays, we expect that the formal date that we send the first
application in will not be immediate, but we will continue to
report material developments on a
timely basis."
Dr. Averback said "Patients treated with FT in
long-term U.S. clinical trials had very low incidence of prostate
cancer after 4 years, much lower than expected from comparable
population studies, and statistically much lower than placebo
treated subjects in the studies. That is very exciting to us.
Patients treated with FT in long-term US clinical trials also had
statistically very low incidence of acute urinary
retention after 4 years, and statistically less need for
invasive surgery -- both of which are also very exciting to us.
These long-term clinical trials showed none of the typical sexual
worsening often seen in long-term treatment for this common
condition. That is good news for countless people in this
unfortunate situation."
"The clinical studies prospectively assessed the
benefits of fexapotide for those patients who had failed on oral
medications or were intolerant of their side effects or who did not
want to take a daily medication for the rest of their lives. The
studies showed in these patients where their treatment had failed
with conventional medications, that there was a highly
statistically significant benefit for them in their long-term
symptom reduction after Fexapotide treatment." he said.
Fexapotide treatment involves a single brief
well tolerated office administration of Fexapotide given by
injection with prostate ultrasound localization, with no
anesthesia or catheter required.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2020, and its Quarterly Reports.
For Further Information
Contact: Randall
Lanham Nymox
Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024